May 2018: Lipomedix received the approval of a new USPT Patent Application (#9937261) for the combined use of Promitil with Radiotherapy entitled “Combination Therapy Comprising a Liposomal Prodrug of Mitomycin C and Radiotherapy”
July-2016: News release from UNC-Chapel Hill Cancer Center on a recently published joint paper with Lipomedix on our product Promitil and radiotherapy (http://unclineberger.org/news/wang-radiation)
May 2016: Lipomedix received a 2million shekel grant from the Israel Chief Scientist Office for the funding of the project “Development of Promitil a pegylated liposomal MMC- prodrug”
Dr. Alberto Gabizon, CEO and Chief Scientist of Lipomedix, lectured at the 3rd Global Bioequivalence Harmonization Initiative Conference which took place in Amsterdam, April 12-13, 2018 (http://www.eufeps.org/conferences/3rd_GBHI) on "Liposome-based therapeutics: Impact of formulation on pharmacokinetics and pharmacodynamics"
Poster entitled “A Multidrug Formulation of Pegylated Liposomes with Co-Encapsulated Alendronate, Doxorubicin, and Mitomycin-C Lipid–Based Prodrug for Chemo-Immunotherapy of Cancer” presented at the ICRS meeting, September 14-16, 2016, Maalot, Israel
Poster entitled “A Phase 1B Study of Pegylated Liposomal Mitomycin-C Prodrug with or without Capecitabine and Bevacizumab in Third Line Chemotherapy of Colorectal Cancer” presented at the ESMO meeting, October 10-13, 2016, Copenhagen, Denmark
Poster entitled “Pharmacologic studies of a prodrug of mitomycin C in pegylated liposomes (Promitil®)” presented at Nano Israel Conference, February 22-23, Tel Aviv University, Israel
Lipomedix is seeking additional funding from private investors or investment groups for clinical studies leading to registration of Promitil® in US and world markets for advanced metastatic colo-rectal cancer, and for further developing its pipeline. Prospective investors are invited to meet with the Company’s management team to discuss an investment in the Company.